Headquartered in Salt Lake City, UT Fiscal year ends December NASDAQ: CODX co-dx.com
Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets diagnostics technologies utilizing the detection and analysis of nucleic acid molecules (DNA or RNA). The company's core platform is the Co-Dx PCR system, an integrated molecular diagnostics ecosystem combining instrumentation, assays, cloud connectivity, and AI-enabled capabilities designed for at-home and point-of-care testing applications. Key products under development include the Co-Dx PCR Flu A/B & RSV multiplex test (pending FDA 510(k) review) and tuberculosis diagnostics. The company also operates the Vector Smart decentralized vector surveillance platform used by mosquito abatement districts across 21 U.S. states. Co-Diagnostics pursues international commercialization through joint ventures including CoSara Diagnostics in India (focused on TB diagnostics) and CoMira Diagnostics in Saudi Arabia (targeting the MENA region). The company's platform and associated tests have not been cleared by the FDA and are not yet available for commercial sale in the United States. Updated
Wednesday afternoon's top analyst upgrades and downgrades included Inovio Pharmaceuticals, McDonald’s, Orchard Therapeutics, VBI Vaccines and Wingstop.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including Co-Diagnostics, DocuSign, Dow, Nomura, Sea and more.
Tuesday's top analyst upgrades and downgrades included AECOM, BBVA, Cheniere Energy, Chevron, DraftKings, General Motors, Moderna, Novavax, Palo Alto Networks and Penn National Gaming.
Co-Diagnostics announced Tuesday that it has entered into an agreement with Arches Research to expand Arches' COVID-19 testing services using Co-Diagnostics’ test kit.
Friday's top analyst upgrades and downgrades included AES, Applied Materials, Bloom Energy, Chimera Investment, Co-Diagnostics, FirstEnergy, Home Depot, Marriott, Target, Tesla and Walmart.
Investors look at Aytu BioScience as it looks at expanding in the COVID testing field.
Aytu BioScience has a distribution agreement for a COVID-19 rapid test and is developing a potential UV light-based treatment.
Wednesday's top analyst upgrades and downgrades included AbbVie, American Electric Power, Anheuser-Busch InBev, Arconic, Baidu, Best Buy, Co-Diagnostics, Cree, Exelon, Home Depot, NRG Energy, T-Mobile and Walmart.
Monday's top analyst upgrades and downgrades included Apple, Best Buy, Cinemark, Co-Diagnostics, DraftKings, Energizer, Novavax, Nvidia, Palo Alto Networks and Petrobras.
This specialty pharmaceutical company is making good progress on multiple fronts, including changes to its board of directors and with its test for and treatment of COVID-19.
Aytu BioScience has been one of the biggest winners in the fight against the novel coronavirus. The company is sending 2,700 COVID-19 rapid tests to Denver for use with first responders.
Co-Diagnostics has been the toast of Wall Street after it went from penny stock status to a revered coronavirus testing stock.
GenMark Diagnostics shares shot up early on Wednesday after the company provided an update on its quarterly numbers and where it stands with its coronavirus test.
Co-Diagnostics shares popped on Monday after the company announced a key update from the FDA on its COVID-19 test kit.
Becton, Dickinson is officially throwing its hat in the ring to fight COVID-19. Specifically, this firm is working on the front end by testing for the disease and antibodies that have been…
Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets diagnostics technologies utilizing the detection and analysis of nucleic acid molecules (DNA or RNA).
The Wall Street consensus 12-month price target for CODX is $4.00.
